Upstream Bio, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
UPB Nasdaq 2830 upstreambio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Upstream Bio, Inc.

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026 - Jun 8th, 2026 5:00 am
Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - Jun 3rd, 2026 5:00 am
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference - May 18th, 2026 9:30 am
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates - May 13th, 2026 6:20 am
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights - May 13th, 2026 5:00 am
Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference - Apr 17th, 2026 5:00 am
Wix downgraded, TripAdvisor upgraded: Wall Street's top analyst calls - Mar 27th, 2026 7:46 am
Here Are Friday’s Top Wall Street Analyst Research Calls: Brown-Forman, Chord Energy, Emerson Electric, FuboTV, Genmab, Honeywell, Knight-Swift, Wix.Com, and More - Mar 27th, 2026 6:04 am
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results - Mar 26th, 2026 5:00 am
Chronic Rhinosinusitis with Nasal Polyps Market Shows Strong Upward Momentum During the Forecast Period (2026-2036) as Demand for Advanced Therapies Rises | DelveInsight - Mar 5th, 2026 3:31 pm
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting - Mar 1st, 2026 7:45 am
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026 - Feb 26th, 2026 5:00 am
Upstream Bio to Participate in Upcoming March Investor Conferences - Feb 25th, 2026 5:00 am
Upstream Bio Shares Phase II VALIANT Data: Verekitug Cuts Severe Asthma Exacerbations Up to 56% - Feb 15th, 2026 5:11 pm
Companies Like Upstream Bio (NASDAQ:UPB) Are In A Position To Invest In Growth - Feb 15th, 2026 6:03 am
Upstream Bio’s stock drops 47% on verekitug Phase II asthma data - Feb 12th, 2026 5:55 am
Upstream Bio Crashes After Asthma Drug Succeeds — With The Wrong Dose - Feb 11th, 2026 2:04 pm
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma - Feb 11th, 2026 4:00 am
Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill - Feb 11th, 2026 2:33 am
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma - Feb 10th, 2026 4:00 pm